Skye Bioscience, Inc. (SKYE) 10-Year Financial Performance & Capital Metrics

SKYE • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutSkye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.Show more

Revenue $0
EBITDA -$30M +13.6%
Net Income -$27M +29.4%
EPS (Diluted) -0.73 +86.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -80.48%
ROIC -3192.59% -50.4%
Debt/Equity 0.01
Interest Coverage -31.20 +18.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-141.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-52.38%

ROCE

10Y Avg-679.37%

5Y Avg-818.92%

3Y Avg-1153.98%

Latest-90.85%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	9.95K	14.92K	8.04K	1.54K	1.46K	1.87K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-9.95K	-14.92K	-8.04K	-1.54K	-1.46K	-1.87K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.5%	0.46%	0.81%	0.05%	-0.28%	1%	-	-	-
Operating Expenses+	4.32M	4.47M	3.86M	4.69M	6.63M	6.29M	7.85M	18.31M	34.74M	30.19M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.74M	3.53M	3.55M	4.36M	4.39M	4.34M	4.92M	6.09M	7.85M	17.73M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	576.09K	939.04K	311.3K	329.97K	2.24M	1.94M	2.93M	6.01M	5.82M	18.7M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	2K	0	0	6.21M	21.06M	-6.23M
Operating Income+	-4.32M	-4.47M	-3.86M	-4.69M	-6.63M	-6.29M	-7.85M	-18.31M	-34.74M	-30.19M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.58%	-0.04%	0.14%	-0.22%	-0.41%	0.05%	-0.25%	-1.33%	-0.9%	0.13%
EBITDA+	-4.31M	-4.46M	-4.62M	-4.69M	-6.63M	-6.29M	-7.81M	-18.2M	-34.61M	-29.89M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.58%	-0.03%	-0.04%	-0.02%	-0.41%	0.05%	-0.24%	-1.33%	-0.9%	0.14%
D&A (Non-Cash Add-back)	9.95K	14.92K	-759K	1.54K	1.46K	1.87K	34.13K	115K	124.25K	298.64K
EBIT	0	0	-3.09M	-19.1M	2.04M	-5.85M	-7.75M	-18.81M	-36.74M	-25.59M
Net Interest Income+	0	0	0	-94.68K	-1M	-706.36K	-767.51K	-644.76K	-806.3K	2.3M
Interest Income	0	0	0	84	26	29	3	19.01K	99.97K	3.26M
Interest Expense	522.34K	0	667	94.76K	1M	706.38K	767.51K	663.77K	906.27K	967.6K
Other Income/Expense	-522.34K	1.29M	766.53K	-14.5M	7.69M	-270K	-672.37K	-1.16M	-2.91M	3.64M
Pretax Income+	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.47M	-37.64M	-26.56M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	1.72K	1.6K	1.6K	1.64K	1.6K	1.6K	2.1K	6.74K	3.6K	10.07K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.48M	-37.64M	-26.57M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.77%	0.34%	0.03%	-5.2%	1.05%	-7.24%	-0.3%	-1.29%	-0.93%	0.29%
Net Income (Continuing)	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.48M	-37.64M	-26.57M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-70.93	-39.90	-25.62	-36.51	1.98	-7.46	-5.00	-8.77	-5.37	-0.73
EPS Growth %	-0.09%	0.44%	0.36%	-0.43%	1.05%	-4.77%	0.33%	-0.75%	0.39%	0.86%
EPS (Basic)	-71.45	-41.93	-25.62	-36.51	1.98	-7.11	-5.00	-8.77	-5.37	-0.73
Diluted Shares Outstanding	68.25K	79.65K	120.77K	525.78K	532.01K	925.68K	1.63M	2.22M	7.01M	36.49M
Basic Shares Outstanding	67.75K	75.79K	120.77K	525.78K	532.01K	922.99K	1.63M	2.22M	7.01M	36.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.45M	279.49K	555.81K	1.95M	1.99M	2.66M	9.61M	8.94M	11.65M	70.83M
Cash & Short-Term Investments	3.22M	64.82K	259.95K	1.85M	1.83M	2.47M	8.98M	1.24M	1.26M	68.42M
Cash Only	3.22M	64.82K	259.95K	1.85M	1.83M	2.47M	8.98M	1.24M	1.26M	68.42M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	74.12K	158.24K	5.07K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	73.63K	44.51K	4.43K	7.12K	12.09K	4.84K	61.44K	6.74M	9.64M	207.21K
Total Non-Current Assets+	57.27K	43.87K	1.41K	3.44K	1.98K	7.34K	242.99K	167.35K	289.57K	1.94M
Property, Plant & Equipment	13.38K	9.58K	1.41K	3.44K	1.98K	7.34K	234.68K	159.04K	281.26K	1.88M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	43.88K	34.29K	0	0	0	0	8.31K	8.31K	8.31K	53.91K
Total Assets+	3.51M	323.36K	557.22K	1.96M	2M	2.67M	9.86M	9.11M	11.94M	72.76M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	9.08%	-0.91%	0.72%	2.51%	0.02%	0.34%	2.69%	-0.08%	0.31%	5.09%
Total Current Liabilities+	581.86K	661.96K	805.97K	15.94M	970.82K	787.2K	3.91M	12.12M	13.9M	4.34M
Accounts Payable	125.36K	274.65K	100.92K	15.6K	139.81K	381.37K	900.01K	1.79M	956.75K	569.25K
Days Payables Outstanding	4.6K	6.72K	4.58K	3.69K	34.9K	74.36K	-	-	-	-
Short-Term Debt	0	0	235K	0	0	64.06K	1.97M	1.9M	4.37M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	84.09K	121.27K	271.71K	15.74M	410.6K	38.57K	435.57K	7.48M	969.62K	549.15K
Current Ratio	5.94x	0.42x	0.69x	0.12x	2.05x	3.38x	2.46x	0.74x	0.84x	16.32x
Quick Ratio	5.94x	0.42x	0.69x	0.12x	2.05x	3.38x	2.46x	0.74x	0.84x	16.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.46M	1.11M	551.32K	1.58M	477.87K	1.43M	78.7K	0	171.23K	273.16K
Long-Term Debt	0	0	0	1.36M	387.07K	1.43M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	78.7K	0	171.23K	273.16K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.46M	1.11M	551.32K	219.45K	90.8K	0	0	0	0	0
Total Liabilities	3.04M	1.77M	1.36M	17.52M	1.45M	2.22M	3.99M	12.12M	14.07M	4.61M
Total Debt+	0	0	235K	1.36M	387.07K	1.5M	2.14M	1.98M	4.62M	455.59K
Net Debt	-3.22M	-64.82K	-24.95K	-492.41K	-1.44M	-971.61K	-6.85M	738K	3.36M	-67.96M
Debt / Equity	-	-	-	-	0.71x	3.32x	0.36x	-	-	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-8.27x	-	-5785.61x	-49.52x	-6.63x	-8.90x	-10.22x	-27.59x	-38.33x	-31.20x
Total Equity+	471K	-1.45M	-800.08K	-15.56M	548.06K	450.79K	5.86M	-3.01M	-2.13M	68.15M
Equity Growth %	2.04%	-4.08%	0.45%	-18.45%	1.04%	-0.18%	12.01%	-1.51%	0.29%	32.97%
Book Value per Share	6.90	-18.22	-6.63	-29.60	1.03	0.49	3.61	-1.35	-0.30	1.87
Total Shareholders' Equity	471K	-1.45M	-800.08K	-15.56M	548.06K	450.79K	5.86M	-3.01M	-2.13M	68.15M
Common Stock	19.9K	21.56K	33.62K	133.91K	182.9K	288.07K	476.11K	3.65K	12.35K	30.98K
Retained Earnings	-7.76M	-10.94M	-14.03M	-33.23M	-32.17M	-38.73M	-47.26M	-66.74M	-104.38M	-130.95M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.73M	-3.55M	-3.3M	-3.94M	-6.03M	-6.05M	-6.47M	-12.74M	-13.95M	-25.24M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.12%	0.05%	0.07%	-0.2%	-0.53%	-0%	-0.07%	-0.97%	-0.09%	-0.81%
Net Income	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.48M	-37.64M	-26.57M
Depreciation & Amortization	9.95K	14.92K	8.04K	1.54K	1.46K	1.87K	34.13K	115K	124.25K	298.64K
Stock-Based Compensation	414.34K	706.37K	608.68K	674.96K	680.46K	302.74K	869.21K	629.03K	987.51K	8.32M
Deferred Taxes	0	-1.24M	0	0	-8.69M	0	0	0	0	0
Other Non-Cash Items	1.11M	98.56K	-496.78K	14.47M	629.29K	107.76K	497.01K	6.76M	23.05M	-4.66M
Working Capital Changes	-418.57K	40.52K	-323.85K	100.19K	295.71K	94.19K	646.94K	-761.9K	-469.31K	-2.63M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-274.14K	149.29K	-173.73K	-85.32K	134.21K	241.56K	518.64K	799.74K	-701.28K	-586.53K
Cash from Investing+	-1.98K	-11.12K	-19.65K	-4.38K	0	-7.23K	-90.87K	5.21M	6.6M	-245.62K
Capital Expenditures	-1.98K	-11.12K	-19.65K	-4.38K	0	-7.23K	-90.87K	-28.06K	-12.55K	-1.6M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	-66.46K	6.61M	0
Cash from Financing+	6.74M	407.67K	3.51M	5.54M	6M	6.7M	13.08M	-208.79K	16.44M	83.56M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	98.7K	4.08M	48.53K	7.02M	0	-6.03K	5.62K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.73M	-3.56M	-3.32M	-3.95M	-6.03M	-6.06M	-6.57M	-12.77M	-13.96M	-26.84M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.1%	0.04%	0.07%	-0.19%	-0.53%	-0.01%	-0.08%	-0.95%	-0.09%	-0.92%
FCF per Share	-54.65	-44.75	-27.47	-7.51	-11.33	-6.55	-4.04	-5.75	-1.99	-0.74
FCF Conversion (FCF/Net Income)	0.77x	1.12x	1.07x	0.21x	-5.73x	0.92x	0.76x	0.65x	0.37x	0.95x
Interest Paid	0	0	0	23.33K	371.42K	117.46K	44.09K	333.55K	198.35K	433.34K
Taxes Paid	1.72K	0	1.63K	1.64K	1.6K	1.6K	1.6K	6.74K	3.6K	5.2K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-55492.45%	-	-	-	191.95%	-1313.72%	-269.9%	-1364.2%	-	-80.48%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-2123.19%	-3192.59%
Debt / Equity	-	-	-	-	0.71x	3.32x	0.36x	-	-	0.01x
Interest Coverage	-8.27x	-	-5785.61x	-49.52x	-6.63x	-8.90x	-10.22x	-27.59x	-38.33x	-31.20x
FCF Conversion	0.77x	1.12x	1.07x	0.21x	-5.73x	0.92x	0.76x	0.65x	0.37x	0.95x

Frequently Asked Questions

Growth & Financials

Skye Bioscience, Inc. (SKYE) grew revenue by 0.0% over the past year. Growth has been modest.

Skye Bioscience, Inc. (SKYE) reported a net loss of $51.2M for fiscal year 2024.

Dividend & Returns

Skye Bioscience, Inc. (SKYE) has a return on equity (ROE) of -80.5%. Negative ROE indicates the company is unprofitable.

Skye Bioscience, Inc. (SKYE) had negative free cash flow of $9.22B in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Skye Bioscience, Inc. (SKYE) 10-Year Financial Performance & Capital Metrics

SKYE • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

Revenue $0
EBITDA -$30M +13.6%
Net Income -$27M +29.4%
EPS (Diluted) -0.73 +86.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -80.48%
ROIC -3192.59% -50.4%
Debt/Equity 0.01
Interest Coverage -31.20 +18.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-141.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-52.38%

ROCE

10Y Avg-679.37%

5Y Avg-818.92%

3Y Avg-1153.98%

Latest-90.85%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	9.95K	14.92K	8.04K	1.54K	1.46K	1.87K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-9.95K	-14.92K	-8.04K	-1.54K	-1.46K	-1.87K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.5%	0.46%	0.81%	0.05%	-0.28%	1%	-	-	-
Operating Expenses+	4.32M	4.47M	3.86M	4.69M	6.63M	6.29M	7.85M	18.31M	34.74M	30.19M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.74M	3.53M	3.55M	4.36M	4.39M	4.34M	4.92M	6.09M	7.85M	17.73M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	576.09K	939.04K	311.3K	329.97K	2.24M	1.94M	2.93M	6.01M	5.82M	18.7M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	2K	0	0	6.21M	21.06M	-6.23M
Operating Income+	-4.32M	-4.47M	-3.86M	-4.69M	-6.63M	-6.29M	-7.85M	-18.31M	-34.74M	-30.19M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.58%	-0.04%	0.14%	-0.22%	-0.41%	0.05%	-0.25%	-1.33%	-0.9%	0.13%
EBITDA+	-4.31M	-4.46M	-4.62M	-4.69M	-6.63M	-6.29M	-7.81M	-18.2M	-34.61M	-29.89M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.58%	-0.03%	-0.04%	-0.02%	-0.41%	0.05%	-0.24%	-1.33%	-0.9%	0.14%
D&A (Non-Cash Add-back)	9.95K	14.92K	-759K	1.54K	1.46K	1.87K	34.13K	115K	124.25K	298.64K
EBIT	0	0	-3.09M	-19.1M	2.04M	-5.85M	-7.75M	-18.81M	-36.74M	-25.59M
Net Interest Income+	0	0	0	-94.68K	-1M	-706.36K	-767.51K	-644.76K	-806.3K	2.3M
Interest Income	0	0	0	84	26	29	3	19.01K	99.97K	3.26M
Interest Expense	522.34K	0	667	94.76K	1M	706.38K	767.51K	663.77K	906.27K	967.6K
Other Income/Expense	-522.34K	1.29M	766.53K	-14.5M	7.69M	-270K	-672.37K	-1.16M	-2.91M	3.64M
Pretax Income+	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.47M	-37.64M	-26.56M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	1.72K	1.6K	1.6K	1.64K	1.6K	1.6K	2.1K	6.74K	3.6K	10.07K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.48M	-37.64M	-26.57M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.77%	0.34%	0.03%	-5.2%	1.05%	-7.24%	-0.3%	-1.29%	-0.93%	0.29%
Net Income (Continuing)	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.48M	-37.64M	-26.57M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-70.93	-39.90	-25.62	-36.51	1.98	-7.46	-5.00	-8.77	-5.37	-0.73
EPS Growth %	-0.09%	0.44%	0.36%	-0.43%	1.05%	-4.77%	0.33%	-0.75%	0.39%	0.86%
EPS (Basic)	-71.45	-41.93	-25.62	-36.51	1.98	-7.11	-5.00	-8.77	-5.37	-0.73
Diluted Shares Outstanding	68.25K	79.65K	120.77K	525.78K	532.01K	925.68K	1.63M	2.22M	7.01M	36.49M
Basic Shares Outstanding	67.75K	75.79K	120.77K	525.78K	532.01K	922.99K	1.63M	2.22M	7.01M	36.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.45M	279.49K	555.81K	1.95M	1.99M	2.66M	9.61M	8.94M	11.65M	70.83M
Cash & Short-Term Investments	3.22M	64.82K	259.95K	1.85M	1.83M	2.47M	8.98M	1.24M	1.26M	68.42M
Cash Only	3.22M	64.82K	259.95K	1.85M	1.83M	2.47M	8.98M	1.24M	1.26M	68.42M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	74.12K	158.24K	5.07K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	73.63K	44.51K	4.43K	7.12K	12.09K	4.84K	61.44K	6.74M	9.64M	207.21K
Total Non-Current Assets+	57.27K	43.87K	1.41K	3.44K	1.98K	7.34K	242.99K	167.35K	289.57K	1.94M
Property, Plant & Equipment	13.38K	9.58K	1.41K	3.44K	1.98K	7.34K	234.68K	159.04K	281.26K	1.88M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	43.88K	34.29K	0	0	0	0	8.31K	8.31K	8.31K	53.91K
Total Assets+	3.51M	323.36K	557.22K	1.96M	2M	2.67M	9.86M	9.11M	11.94M	72.76M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	9.08%	-0.91%	0.72%	2.51%	0.02%	0.34%	2.69%	-0.08%	0.31%	5.09%
Total Current Liabilities+	581.86K	661.96K	805.97K	15.94M	970.82K	787.2K	3.91M	12.12M	13.9M	4.34M
Accounts Payable	125.36K	274.65K	100.92K	15.6K	139.81K	381.37K	900.01K	1.79M	956.75K	569.25K
Days Payables Outstanding	4.6K	6.72K	4.58K	3.69K	34.9K	74.36K	-	-	-	-
Short-Term Debt	0	0	235K	0	0	64.06K	1.97M	1.9M	4.37M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	84.09K	121.27K	271.71K	15.74M	410.6K	38.57K	435.57K	7.48M	969.62K	549.15K
Current Ratio	5.94x	0.42x	0.69x	0.12x	2.05x	3.38x	2.46x	0.74x	0.84x	16.32x
Quick Ratio	5.94x	0.42x	0.69x	0.12x	2.05x	3.38x	2.46x	0.74x	0.84x	16.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.46M	1.11M	551.32K	1.58M	477.87K	1.43M	78.7K	0	171.23K	273.16K
Long-Term Debt	0	0	0	1.36M	387.07K	1.43M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	78.7K	0	171.23K	273.16K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	2.46M	1.11M	551.32K	219.45K	90.8K	0	0	0	0	0
Total Liabilities	3.04M	1.77M	1.36M	17.52M	1.45M	2.22M	3.99M	12.12M	14.07M	4.61M
Total Debt+	0	0	235K	1.36M	387.07K	1.5M	2.14M	1.98M	4.62M	455.59K
Net Debt	-3.22M	-64.82K	-24.95K	-492.41K	-1.44M	-971.61K	-6.85M	738K	3.36M	-67.96M
Debt / Equity	-	-	-	-	0.71x	3.32x	0.36x	-	-	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-8.27x	-	-5785.61x	-49.52x	-6.63x	-8.90x	-10.22x	-27.59x	-38.33x	-31.20x
Total Equity+	471K	-1.45M	-800.08K	-15.56M	548.06K	450.79K	5.86M	-3.01M	-2.13M	68.15M
Equity Growth %	2.04%	-4.08%	0.45%	-18.45%	1.04%	-0.18%	12.01%	-1.51%	0.29%	32.97%
Book Value per Share	6.90	-18.22	-6.63	-29.60	1.03	0.49	3.61	-1.35	-0.30	1.87
Total Shareholders' Equity	471K	-1.45M	-800.08K	-15.56M	548.06K	450.79K	5.86M	-3.01M	-2.13M	68.15M
Common Stock	19.9K	21.56K	33.62K	133.91K	182.9K	288.07K	476.11K	3.65K	12.35K	30.98K
Retained Earnings	-7.76M	-10.94M	-14.03M	-33.23M	-32.17M	-38.73M	-47.26M	-66.74M	-104.38M	-130.95M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.73M	-3.55M	-3.3M	-3.94M	-6.03M	-6.05M	-6.47M	-12.74M	-13.95M	-25.24M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.12%	0.05%	0.07%	-0.2%	-0.53%	-0%	-0.07%	-0.97%	-0.09%	-0.81%
Net Income	-4.84M	-3.18M	-3.09M	-19.19M	1.05M	-6.56M	-8.52M	-19.48M	-37.64M	-26.57M
Depreciation & Amortization	9.95K	14.92K	8.04K	1.54K	1.46K	1.87K	34.13K	115K	124.25K	298.64K
Stock-Based Compensation	414.34K	706.37K	608.68K	674.96K	680.46K	302.74K	869.21K	629.03K	987.51K	8.32M
Deferred Taxes	0	-1.24M	0	0	-8.69M	0	0	0	0	0
Other Non-Cash Items	1.11M	98.56K	-496.78K	14.47M	629.29K	107.76K	497.01K	6.76M	23.05M	-4.66M
Working Capital Changes	-418.57K	40.52K	-323.85K	100.19K	295.71K	94.19K	646.94K	-761.9K	-469.31K	-2.63M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-274.14K	149.29K	-173.73K	-85.32K	134.21K	241.56K	518.64K	799.74K	-701.28K	-586.53K
Cash from Investing+	-1.98K	-11.12K	-19.65K	-4.38K	0	-7.23K	-90.87K	5.21M	6.6M	-245.62K
Capital Expenditures	-1.98K	-11.12K	-19.65K	-4.38K	0	-7.23K	-90.87K	-28.06K	-12.55K	-1.6M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	-66.46K	6.61M	0
Cash from Financing+	6.74M	407.67K	3.51M	5.54M	6M	6.7M	13.08M	-208.79K	16.44M	83.56M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	98.7K	4.08M	48.53K	7.02M	0	-6.03K	5.62K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.73M	-3.56M	-3.32M	-3.95M	-6.03M	-6.06M	-6.57M	-12.77M	-13.96M	-26.84M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.1%	0.04%	0.07%	-0.19%	-0.53%	-0.01%	-0.08%	-0.95%	-0.09%	-0.92%
FCF per Share	-54.65	-44.75	-27.47	-7.51	-11.33	-6.55	-4.04	-5.75	-1.99	-0.74
FCF Conversion (FCF/Net Income)	0.77x	1.12x	1.07x	0.21x	-5.73x	0.92x	0.76x	0.65x	0.37x	0.95x
Interest Paid	0	0	0	23.33K	371.42K	117.46K	44.09K	333.55K	198.35K	433.34K
Taxes Paid	1.72K	0	1.63K	1.64K	1.6K	1.6K	1.6K	6.74K	3.6K	5.2K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-55492.45%	-	-	-	191.95%	-1313.72%	-269.9%	-1364.2%	-	-80.48%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-	-	-2123.19%	-3192.59%
Debt / Equity	-	-	-	-	0.71x	3.32x	0.36x	-	-	0.01x
Interest Coverage	-8.27x	-	-5785.61x	-49.52x	-6.63x	-8.90x	-10.22x	-27.59x	-38.33x	-31.20x
FCF Conversion	0.77x	1.12x	1.07x	0.21x	-5.73x	0.92x	0.76x	0.65x	0.37x	0.95x

Frequently Asked Questions

Growth & Financials

Skye Bioscience, Inc. (SKYE) grew revenue by 0.0% over the past year. Growth has been modest.

Skye Bioscience, Inc. (SKYE) reported a net loss of $51.2M for fiscal year 2024.

Dividend & Returns

Skye Bioscience, Inc. (SKYE) has a return on equity (ROE) of -80.5%. Negative ROE indicates the company is unprofitable.

Skye Bioscience, Inc. (SKYE) had negative free cash flow of $9.22B in fiscal year 2024, likely due to heavy capital investments.